ロード中...
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
Background: Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim...
保存先:
| 出版年: | Front Neurol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079654/ https://ncbi.nlm.nih.gov/pubmed/33935948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.650530 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|